Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Auto-sampler Stability of Samples – V 2.0

Posted on By

BA-BE Studies: SOP for Auto-sampler Stability of Samples – V 2.0

Standard Operating Procedure for Auto-sampler Stability of Analyte in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/178/2025
Supersedes SOP/BA-BE/178/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the process for evaluating the auto-sampler stability of analytes in processed plasma samples stored in the instrument tray during LC-MS/MS runs in bioavailability/bioequivalence (BA/BE) studies.

2. Scope

This SOP is applicable to all validated bioanalytical methods used in BA/BE studies, specifically for assessing the stability of analytes held at auto-sampler temperature (usually 4–10°C) for prolonged durations before injection.

3. Responsibilities

  • Bioanalytical Analyst: Prepares and analyzes auto-sampler stability samples and maintains logs.
  • Supervisor: Ensures compliance with time schedules and evaluates results.
  • QA Officer: Reviews documentation and approves inclusion in validation or study report.
See also  BA-BE Studies: SOP for Ensuring Sample Integrity Before Analysis - V 2.0

4. Accountability

The Bioanalytical Head is accountable for ensuring the auto-sampler stability studies are conducted according to validation protocols and documented accurately for regulatory compliance.

5. Procedure

5.1 Sample Preparation

  1. Prepare a minimum of six replicates each for Low QC (LQC) and High QC (HQC) samples.
  2. Label each vial clearly with:
    • Sample ID
    • QC Level
    • Analyte Name
    • Preparation Date & Time
    • Auto-sampler Stability
  3. Record sample details in Annexure-1: Auto-sampler Stability Log.

5.2 Exposure in Auto-sampler

  1. Place processed QC samples in the auto-sampler tray set to validated temperature (e.g., 4°C).
  2. Expose samples for a predefined duration (e.g., 24, 48, or 72 hours) as specified in the method validation protocol.
  3. Ensure samples remain capped and undisturbed throughout the holding period.
See also  BA-BE Studies: SOP for Integrating BA/BE Studies in Global Clinical Strategy - V 2.0

5.3 Sample Analysis

  1. Inject stability samples along with fresh calibration curve and system suitability QC samples.
  2. Use validated LC-MS/MS method and record analyte concentrations.

5.4 Acceptance Criteria

  1. Mean concentrations of LQC and HQC must be within ±15% of their nominal values.
  2. %CV for each QC level must be ≤15%.
  3. Summarize findings in Annexure-2: Auto-sampler Stability Summary.

5.5 Documentation and Reporting

  1. Compile chromatograms, raw data printouts, and analysis reports.
  2. Prepare and submit a report to QA for approval.
  3. Include the approved report in the study validation or final submission dossier.

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • LQC: Low Quality Control
  • HQC: High Quality Control
  • %CV: Percent Coefficient of Variation
  • QA: Quality Assurance

7. Documents

  1. Auto-sampler Stability Log – Annexure-1
  2. Auto-sampler Stability Summary – Annexure-2

See also  BA-BE Studies: SOP for Documenting Concomitant Medication Usage - V 2.0

8. References

  • ICH M10: Bioanalytical Method Validation
  • US FDA Guidance for Industry: Bioanalytical Method Validation (2022)
  • Internal Method Validation Protocol

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Auto-sampler Stability Log

Sample ID QC Level Prep Date Tray Temp Start Time End Time Analyst
BE178-AS-01 LQC 16/04/2025 4°C 10:00 10:00 (18/04/2025) Rajesh Kumar

Annexure-2: Auto-sampler Stability Summary

QC Level Nominal (ng/mL) Mean Measured %CV % Difference Status
LQC 20.0 19.2 4.3 -4.0% Accepted
HQC 1500.0 1496.5 3.1 -0.2% Accepted

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial SOP Issuance New SOP QA Head
17/04/2025 2.0 Updated cycle durations, annexures added Method Compliance QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Aerosol: SOP for Conducting Internal Audits for Aerosol Manufacturing – V 2.0
Next Post: Creams: SOP for Monitoring Airborne Particulates in Production Areas – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version